Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by PureTech Health plc

< Previous 1 2 3 4 Next >
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Appoints UBS as UK Corporate Broker
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Health plc – Half-Year Report
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Appoints Michele Holcomb, PhD, to Board of Directors
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Health: Notice of Half-Yearly Results
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Health: Completion of Tender Offer & Total Voting Rights
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Health: Results of the Tender Offer
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Announces Change of Board Role
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Health: Results of Annual General Meeting
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Health: Result of General Meeting
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech to Present at the Jefferies Global Healthcare Conference
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Announces Annual Results for Year Ended December 31, 2023
From PureTech Health plc
Via Business Wire
Tickers PRTC
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.